Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease

Zhu, Kong-Xiang; Song, Pei-Yuan; Heli,; Li, Mu-Peng; Du, Yin-Xiao; Ma, Qin; Peng, Lihua; Chen, Xiao-Ping

doi:10.1007/s00228-020-03024-6

Cited by 6 publications

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared to these genes, 11 genes have unknown clinical trials including ABCG8, AGT, APOB, CYP2B6, CYP2C9, FABP1, KDR, NPPA, NR3C2, NT5C2 , and PTGS1 which are highly suggested for future clinical trials of investigating the related drugs with CAD. Some of these genes had limited studies with pharmacology of CAD including ALDH2 [ 67 ], APOC1 ([ 68 ]), FMO3 [ 69 ], LEPR [ 70 ], P2RY12 [ 71 ], SCARB1 [ 72 ], SH2B3 [ 73 ], SLCO1B1 [ 74 ], TLR4 [ 75 ], EDN1 [ 76 ], NOS3 [ 77 ], ABCG8 [ 78 ], AGT [ 79 ], FABP1 [ 80 ], KDR [ 81 ], NPPA [ 82 ], NR3C2 [ 83 ], NT5C2 [ 84 ], and PTGS1 [ 85 ].…”

Section: Discussionmentioning

confidence: 99%

Pharmacogenomics-based systematic review of coronary artery disease based on personalized medicine procedure

Kazemi Asl,

Rahimzadegan,

Kazemi Asl

2024

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Pharmacogenomics-based systematic review of coronary artery disease based on personalized medicine procedure

Kazemi Asl,

Rahimzadegan,

Kazemi Asl

2024

Heliyon

View full text Add to dashboard Cite

“…Apart from CYP2C19*2 or CYP2C19*3 mutant alleles, polymorphism in the P2Y12 purinoreceptor appears to also be associated with an increase in the risk of ST following PCI, as emphasized by the results of a meta-analysis on 10 studies and 10.810 clopidogrel-treated subjects [114]. Flavin-containing monooxygenase 3 (FMO3) rs1736557 polymorphism has a complementary influence on the response to clopidogrel therapy, and it appears that the FMO3 rs1736557 AA genotype increases the potency of clopidogrel [115].…”

Section: Geneticsmentioning

confidence: 99%

Patient-Related Factors Predicting Stent Thrombosis in Percutaneous Coronary Interventions

Anghel,

Tudurachi,

Tudurachi

et al. 2023

JCM

View full text Add to dashboard Cite

Over the past four decades, percutaneous coronary intervention (PCI) safety and efficacy have significantly improved, particularly with the advent of the drug-eluting stent (DES). First-generation DESs reduced in-stent restenosis rates and targeted lesion revascularization; however, safety issues emerged, due to high incidences of stent thrombosis (ST) linked to death, myocardial infarction, and repeat revascularization. Second-generation DESs were developed to overcome these issues, reducing late-thrombotic-event risk while maintaining anti-restenosis efficacy. Nevertheless, ST still occurs with second-generation DES use. Stent thrombosis etiology is multifaceted, encompassing lesion-, patient-, procedural-, and stent-related factors. Overall, most early-stent-thrombosis cases are linked to procedural and patient-related aspects. Factors like premature discontinuation of dual antiplatelet therapy, resistance to clopidogrel, smoking, diabetes mellitus, malignancy, reduced ejection fraction or undertaking coronary angioplasty for an acute coronary syndrome can increase the risk of stent thrombosis. The aim of this study is to assess patient-related factors that potentially heighten the risk of stent thrombosis, with the objective of pinpointing and addressing modifiable contributors to this risk. By focusing on both patient- and procedure-related factors, a multifaceted approach to coronary revascularization can help minimize complications and maximize long-term benefits in managing ST.

show abstract

“…We have also validated or reported several polymorphisms that affect clopidogrel response in previous studies. [ [14] , [15] , [16] , [17] ]…”

Section: Introductionmentioning

confidence: 99%

CD80 DNA methylation and single-nucleotide polymorphism associated with clopidogrel response: a whole-genome DNA methylation analysis in acute coronary syndrome

Song¹,

Li²,

Peng³

et al. 2023

Research and Practice in Thrombosis and Haemostasis

Self Cite

View full text Add to dashboard Cite

Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease

Cited by 6 publications

References 44 publications

Pharmacogenomics-based systematic review of coronary artery disease based on personalized medicine procedure

Pharmacogenomics-based systematic review of coronary artery disease based on personalized medicine procedure

Patient-Related Factors Predicting Stent Thrombosis in Percutaneous Coronary Interventions

CD80 DNA methylation and single-nucleotide polymorphism associated with clopidogrel response: a whole-genome DNA methylation analysis in acute coronary syndrome

Contact Info

Product

Resources

About